A new day for myeloid genomic profiling: how NGS advancements are providing deeper insight with faster time to results
sponsored by Thermo Fisher Scientific
September 23, 2020
11am EDT / 5pm CEST
The use of genomic profiling for myeloid samples has accelerated in recent years due in part to increasing annotation of disease-associated biomarkers. As this list of relevant biomarkers continues to expand, traditional single-gene testing approaches are becoming infeasible. In this webinar, we’ll showcase the latest advancement in myeloid genomic profiling: The Ion Torrent Oncomine Myeloid Assay GX. This automated next-generation sequencing solution deployed on revolutionary Ion Torrent Genexus System lets you go from myeloid specimen to annotated report in a single day, with minimal user intervention. Learn how this solution addresses key challenges in myeloid molecular testing and see recent data from the University of Pennsylvania Perelman School of Medicine.
- How advances in NGS workflow automation are enabling more laboratories to bring aboard the technology
- How single-day turnaround time for NGS results can address critical challenges with current myeloid molecular profiling methodologies
- The advantages of being able to generate data for all key myeloid mutations rapidly and simultaneously